Medical management of Barrett's esophagus

Gastrointestinal Endoscopy Clinics of North America

Volumn 13, Issue 3, 2003, Pages 405-418

  Lee, Thomas J ^a   Kahrilas, Peter J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CANCER GRADING; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; ESOPHAGUS MUCOSA; GASTROESOPHAGEAL REFLUX; HUMAN; INTESTINE METAPLASIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0042316765     PISSN: 10525157     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-5157(03)00041-2     Document Type: Review

References (74)

1. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 1996;110:614-21.
2. Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, VanDeventer G, DenBesten L, et al. Barrett's esophagus and adenocarcinoma. Annu Rev Med 1987;38:477-92.
3. Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology 1999;117:218-28.
4. Barrett NR. Chronic peptic ulcer of the oesophagus and oesophagitis. Br J Surg 1950;38:175-82.
5. Barrett NR. The lower esophagus lined by columnar epithelium. Surgery 1957;41:881-94.
6. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
7. Lagergren J. [Increased incidence of adenocarcinoma of the esophagus and cardia. Reflux and obesity are strong and independent risk factors according to the SECC study.] Lakartidningen 2000;97:1950-3.
8. Lagergren J, Ye W, Bergstrom R, Nyren O. Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. JAMA 2000;284:961-2.
9. Cohen S, Parkman HP. Heartburn - a serious symptom. N Engl J Med 1999;340:878-9.
10. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40.
11. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-22.
12. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992;103(4):1241-5.
13. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994;344:1533-6.
14. Anonymous. Barrett's esophagus: epidemiological and clinical results of a multicentric survey. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago (GOSPE). Int J Cancer 1991;48(3):364-8.
15. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992;51(Suppl 1):24-9.
16. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
17. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
18. Schnell TG, Sontag SJ, Chejfec G. Adenocarcinomas arising in tongues or short segments of Barrett's esophagus. Dig Dis Sci 1992;37:137-43.
19. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus - the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998;93:1033-6.
20. Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalosvki M. Prospective long-term endoscopic and histological follow-up of short-segment Barrett's esophagus: comparison with traditional long-segment Barrett's esophagus. Am J Gastroenterol 1997;92:407-13.
21. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999;116:277-85.
22. Oberg S, Peters JH, DeMeester TR, Chandrasoma P, Hagen JA, Ireland AP, et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg 1997;226:522-30.
23. Csendes A, Smok G, Sagastume H, Rojas J. Estudio prospectivo endoscopico y biopsico de la prevalencia de metaplasia intestinal en la union gastroesofagica en controles y en pacientes con reflujo gastroesofagico [Biopsy and endoscopic prospective study of the prevalence of intestinal metaplasia in the gastroesophageal junction in controls and in patients with gastroesophageal reflux]. Rev Med Chil 1998;126:155-61.
24. Goldblum JR, Vicari JJ, Falk GW, Rice TW, Peek RM, Easley K, et al. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology 1998;114:633-9.
25. Chen YY, Antonioli DA, Spechler SJ, Zeroogian JM, Goyal RK, Wang HH. Gastroesophageal reflux disease versus Helicobacter pylori infection as the cause of gastric carditis. Mod Pathol 1998;11:950-6.
26. Nandurkar S, Talley NJ, Martin CJ, Ng TH, Adams S. Short-segment Barrett's oesophagus: prevalence, diagnosis, and associations. Gut 1997;40:710-5.
27. Morales TG, Camargo E, Bhattacharyya A, Sampliner RE. Long-term follow-up of intestinal metaplasia of the gastric cardia. Am J Gastroenterol 2000;95:1677-80.
28. Bremner CG, Lynch VP, Ellis Jr FH. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 1970;68:209-16.
29. Adler RH. The lower esophagus lined by columnar epithelium. Its association with hiatal hernia, ulcer, stricture, and tumor. J Thorac Cardiovasc Surg 1963;45:13-34.
30. Hayward J. The lower end of the esophagus. Thorax 1961;16:36-41.
31. Berenson MM, Herbst JJ, Freston JW. Enzyme and ultrastructural characteristics of esophageal columnar epithelium. Am J Dig Dis 1974;19:895-907.
32. Berenson MM, Herbst JJ, Freston JW. Esophageal columnar epithelial β-galactosidase and β-glucuronidase. Gastroenterology 1975;68:1417-20.
33. Hamilton SR, Yardley JH. Regeneration of cardiac type mucosa and acquisition of Barrett's mucosa after esophagogastrostomy. Gastroenterology 1977;72:669-75.
34. Gillen P, Keeling P, Byrne PJ, West AB, Hennessy TP. Experimental columnar metaplasia in the canine oesophagus. Br J Surg 1988;75:113-5.
35. Berenson MM, Johnson TD, Markowitz NR, Buchi KN, Samowitz WS. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology 1993;104:1686-91.
36. Spechler SJ. Laser photoablation of Barrett's epithelium: burning issues about burning tissues. Gastroenterology 1993;104:1855-8.
37. Lidums I, Holloway R. Motility abnormalities in the columnar-lined esophagus. Gastroenterol Clin North Am 1997;26:519-31.
38. Gillen P, Keeling P, Byrne PJ, Hennessy TP. Barrett's oesophagus: pH profile. Br J Surg 1987;74:774-6.
39. Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus, functional assessment, proposed pathogenesis, and surgical therapy. Arch Surg 1983;118:543-9.
40. Singh P, Taylor RH, Colin-Jones DG. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's esophagus is present. Am J Gastroenterol 1994;89:349-56.
41. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 1999;94:2054-9.
42. Chak A, Lee T, Kinnard MF, Brock W, Faulx A, Willis J, et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002;51:323-8.
43. Jochem VJ, Fuerst PA, Fromkes JJ. Familial Barrett's esophagus associated with adenocarcinoma. Gastroenterology 1992;102:1400-2.
44. Eng C, Spechler SJ, Ruben R, Li FP. Familial Barrett's esophagus and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 1993;2:397-9.
45. Crabb DW, Berk MA, Hall TR, Conneally PM, Biegel AA, Lehman GA. Familial gastroesophageal reflux and development of Barrett's esophagus. Ann Intern Med 1985;103:52-4.
46. Kothari T, Mangla JC, Kalra TM. Barrett's ulcer and treatment with cimetidine. Arch Intern Med 1980;140(4):475-7.
47. Wesdorp IC, Bartelsman J, Schipper ME, Tytgat GN. Effect of long-term treatment with cimetidine and antacids in Barrett's oesophagus. Gut 1981;22(9):724-7.
48. Humphries TJ. Effects of long-term medical treatment with cimetidine and bethanechol in patients with esophagitis and Barrett's esophagus. J Clin Gastroenterol 1987;9(1):28-32.
49. Cooper BT, Barbezat GO. Treatment of Barrett's esophagus with H2 blockers. J Clin Gastroenterol 1987;9(2):139-41.
50. Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988;75(8):760-3.
51. Mann NS, Tsai MF, Nair PK. Barrett's esophagus in patients with symptomatic reflux esophagitis. Am J Gastroenterol 1989;84(12):1494-6.
52. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hyper-secretion in refractory gastroesophageal reflux disease. Gastroenterology 1990;98(3):654-61.
53. Sampliner RE, Garewal HS, Fennerty MB, Aickin M. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci 1990;35(1):93-6.
54. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992;33(9):1155-8.
55. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.
56. Gore S, Healey CJ, Sutton R, Eyre-Brook IA, Gear MW, Shepherd NA, et al. Regression of columnar-lined (Barrett's) oesophagus with continuous omeprazole therapy. Alimentary Pharmacology and Therapeutics 1993;7(6):623-8.
57. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994;89(10):1844-8.
58. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994;121(3):161-7.
59. Neumann CS, Iqbal TH, Cooper BT. Long-term continuous omeprazole treatment of patients with Barrett's oesophagus. Alimentary Pharmacology and Therapeutics 1995;9(4):451-4.
60. Malesci A, Savarino V, Zentilin P, Belicchi M, Mela GS, Lapertosa G, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996;44(6):700-5.
61. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92(4):582-5.
62. Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Alimentary Pharmacology and Therapeutics 1998;12(9):893-7.
63. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999;13(9):1205-9.
64. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am J Gastroenterol 1999;94(12):3420-6.
65. Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999;45(4):489-94.
66. Srinivasan R, Katz PO, Ramakrishnan A, Katzka DA, Vela MF, Castell DO. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Alimentary Pharmacology and Therapeutics 2001;15(4):519-24.
67. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996;98:2120-8.
68. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999;117:327-35.
69. Sampliner RE. New treatments for Barrett's esophagus. Semin Gastrointest Dis 1997;8:68-74.
70. Sampliner RE. The Practice Parameters Committee of the American College of Gastroenterology Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998;93:1028-32.
71. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
72. Sampliner RE. The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97(8):1888-95.
73. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120(7):1630-9.
74. van den Boogert J, van Hillegersberg R, van Staveren HJ, de Bruin RW, van Dekken H, Siersema PD, et al. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. Am J Gastroenterol 1999;94:1153-60.